Medtronic has announced positive results from a study of its next-generation MiniMed 780G automated insulin delivery system.
Its ADAPT study enlisted 82 individuals with Type 1 diabetes who were not currently meeting glycaemic targets. Half of the sample remained on standard care, while the rest transitioned to using the MiniMed 780G. Results demonstrated improvements in glycaemic targets for those using the MiniMed 780G, including a significant and sustained 1.4% HbA1c reduction at six months, a 27.6% increase in time in range and no increase in time in hypoglycaemia.
“The ADAPT study illustrates that insulin pump therapy with advanced algorithms, like that of the MiniMed 780G system, can produce significantly improved clinical results versus the current standard of care,” said Dr.Ohad Cohen, senior global medical affairs director, Medtronic Diabetes. “Studies like this can change how health care systems define standard of care and expand options for people living with diabetes to begin using insulin pumps sooner to improve their glycemic control and help reduce the burden of diabetes.”
The MiniMed 780G system is already available in more than 60 countries and Medtronic is hopeful of FDA clearance this financial year.
To read more, CLICK HERE.